article · Pharmaceuticals
Idiopathic pulmonary fibrosis is a serious, irreversible lung condition with limited treatment options. Disease progression is driven by transforming growth factor-beta signaling, which relies on the molecular chaperone HSP90 to stabilise its receptors. This study evaluated a dual therapy combining alvespimycin, an HSP90 inhibitor, with oleuropein, an olive-derived proteasome activator, in a rat model of bleomycin-induced pulmonary fibrosis. Alvespimycin destabilises the transforming growth factor-beta receptors, while oleuropein promotes their proteasome-dependent degradation. Administering this dual treatment impeded downstream signaling pathways and led to improvements in lung tissue structure and function. The combination therapy also significantly reduced concentrations of key fibrosis markers, including PDGF-BB, TIMP-1, ACTA2, col1a1, and hydroxyproline, demonstrating that accelerated receptor degradation offers an effective antifibrotic strategy in experimental models.
Idiopathic pulmonary fibrosis has very few therapeutic choices and causes irreversible, life-threatening damage to lung tissue. By demonstrating that simultaneously destabilising and degrading key signaling receptors protects lung structure and function, this research identifies an alternative therapeutic mechanism. It offers a fresh target strategy that could inform broader drug discovery programmes aimed at halting or slowing the progression of chronic fibrotic conditions.
This research outlines an early-stage therapeutic approach that could inform drug development efforts by biotechnology and pharmaceutical companies targeting fibrotic diseases. The intervention combines an HSP90 inhibitor with a natural proteasome activator. However, because the study is limited to an experimental rat model, the approach remains far from clinical use and requires substantial preclinical validation, formulation development, and safety testing before advancing toward clinical trials.
AI-generated from the published abstract. Always read the original work before citing.
Idiopathic pulmonary fibrosis (IPF) is an irreversible and life-threatening lung disease of unknown etiology presenting only a few treatment options. TGF-β signaling orchestrates a cascade of events driving pulmonary fibrosis (PF). Notably, recent research has affirmed the augmentation of TGF-β receptor (TβR) signaling via HSP90 activation. HSP90, a molecular chaperone, adeptly stabilizes and folds TβRs, thus intricately regulating TGF-β1 signaling. Our investigation illuminated the impact of alvespimycin, an HSP90 inhibitor, on TGF-β-mediated transcriptional responses by inducing destabilization of TβRs. This outcome stems from the explicit interaction of TβR subtypes I and II with HSP90, where they are clients of this cellular chaperone. It is worth noting that regulation of proteasome-dependent degradation of TβRs is a critical standpoint in the termination of TGF-β signal transduction. Oleuropein, the principal bioactive compound found in Olea europaea, is acknowledged for its role as a proteasome activator. In this study, our aim was to explore the efficacy of a combined therapy involving oleuropein and alvespimycin for the treatment of PF. We employed a PF rat model that was induced by intratracheal bleomycin infusion. The application of this dual therapy yielded a noteworthy impediment to the undesired activation of TGF-β/mothers against decapentaplegic homologs 2 and 3 (SMAD2/3) signaling. Consequently, this novel combination showcased improvements in both lung tissue structure and function while also effectively restraining key fibrosis markers such as PDGF-BB, TIMP-1, ACTA2, col1a1, and hydroxyproline. On a mechanistic level, our findings unveiled that the antifibrotic impact of this combination therapy likely stemmed from the enhanced degradation of both TβRI and TβRII. In conclusion, the utilization of proteasomal activators in conjunction with HSP90 inhibitors ushers in a promising frontier for the management of PF.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/ph16081123
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
